Beyond chronic pain (including nociception and neuropathic pain)9 and thermoregulation disorders, selective high-affinity inhibitors of human TRPV1 are urgently needed in view of the channel’s rapidly emerging role in various psychiatric diseases, such as depression, anxiety, fear, emotional stress, and drug abuse10–14. Here, TRPV1 is linked to psychiatric disorder.